CURRICULUM VITAE

PART I: GENERAL INFORMATION Date prepared: June 12, 2014 NAME: Myles A. Brown OFFICE ADDRESS: Dana-Farber Cancer Institute, D730, 450 Brookline Ave., Boston, MA 02215 ADDRESS: 199 Ward Street, Newton, MA 02459 E-MAIL: Myles_Brown@dfci.harvard.edu URL: http://research.dfci.harvard.edu/brownlab FAX: 617-582-8501 PLACE OF BIRTH: Springfield, MA EDUCATION:

May 1978 B.S. Yale University, New Haven, CT May 1982 M.D. Johns Hopkins University School of Medicine, Baltimore, MD POSTDOCTORAL TRAINING: Internship and Residency: June 1982–July 1983 Intern in Medicine, Brigham and Women's Hospital, Boston, MA July 1983–July 1984 Junior Assistant Resident, Internal Medicine, Brigham and Women's Hospital, Boston, MA July 1984–July 1986 Senior Assistant Resident, Internal Medicine, Brigham and Women's Hospital, Boston, MA Fellowships: July 1982–Dec. 1988 Clinical Fellow in Medicine, Harvard Medical School, Boston MA January 1983–July 1986 Research Fellow, Laboratory of David M. Livingston, Dana-Farber

Cancer Institute, Boston MA July 1986–July 1989 Fellow in Medical Oncology, Dana-Farber Cancer Institute July 1987–July 1988 Visiting Scientist, Laboratory of Phillip A. Sharp, Massachusetts

Institute of Technology, Cambridge MA July 1988–July 1990 Research Scientist, Laboratory of Phillip A. Sharp, Massachusetts

Institute of Technology, Cambridge MA LICENSURE AND CERTIFICATION: July 1986– Massachusetts Medical Licensure September 1986– American Board of Internal Medicine November 1989– Subspecialty Certification in Medical Oncology

1 Myles A. Brown, M.D.

ACADEMIC APPOINTMENTS January 1989–June 1991 Instructor in Medicine, Harvard Medical School July 1991–March 1998 Assistant Professor of Medicine, Harvard Medical School April 1998–June 2006 Associate Professor of Medicine, Harvard Medical School July 2006– Professor of Medicine, Harvard Medical School June 2013- Member, Program in Cell Biology, Programs in Biological and

Biomedical Sciences (BBS), Harvard Medical School HOSPITAL APPOINTMENTS: July 1989 Associate Physician, Brigham and Women's Hospital July 1989–July 1991 Clinical Associate, Dana-Farber Cancer Institute July 1991–July 1992 Assistant Physician, Dana-Farber Cancer Institute July 1991–March 1998 Assistant Professor of Medicine, Dana-Farber Cancer Institute April 1998–June 2006 Associate Professor of Medicine, Dana-Farber Cancer Institute Sept. 2002–Nov. 2010 Chief, Division of Molecular and Cellular Oncology, Dana-Farber

Cancer Institute July 2006– Professor of Medicine, Dana-Farber Cancer Institute Nov. 2010– Director, Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute PRINCIPAL CLINICAL AND HOSPITAL SERVICE RESPONSIBILITIES: 1991– Attending Physician, Adult Clinic, Dana-Farber Cancer Institute 1997– Attending Physician, Brigham and Women’s Hospital MAJOR COMMITTEE ASSIGNMENTS: Dana-Farber Cancer Institute: 1991– Biohazard Control Committee, Member 1992 Biomedical Research Study Grant Committee, Member 1992 Women's Cancers Program Advisory Committee, Member 1993– Biohazard Control Committee, Chairman 1999–2002 Ethics Advisory Committee, Member American Cancer Society: 1996-2002 Peer Review Committee on Carcinogenesis, Nutrition, and the Environment, Member 2008- Member, Council for Extramural Grants 2013- Chair, Council for Extramural Grants National Institute of Health:

2 Myles A. Brown, M.D.

1996, 1998 Biochemical Endocrinology Study Section, NIDDK, 2000, 2001 ad hoc Program Project Review Committee Member 2006 Molecular and Cellular Endocrinology Study Section, NIDDK, ad hoc 2007 ModENCODE Review Committee, NHGRI, Member 2010 Tumor Cell Biology Study Section, NCI, ad hoc 2011- Tumor Cell Biology Study Section, NCI, member Other: 1994, 2002 Army Breast Cancer Research Program, Grant Review 2004, 2005 Committee Member

1995 National Action Plan on Breast Cancer, Grant Review Committee Member

2000-2001 American Association for Cancer Research, Program Committee

Member 2004 University of Cincinnati, U.C. Cancer Center External Advisory

Board Member

2005- Baylor College of Medicine, Breast SPORE External Advisory Committee

2005-2007 American Association for Cancer Research, Special Conferences

Committee Member 2005 DOD, United States Army Medical Research and Material Command

Congressionally Directed Medical Research Programs, Era of Hope Scholars, Scientific Merit Peer Review Committee, Scientist Reviewer

2006-2010 American Association for Cancer Research, Science Policy and Legislative Affairs Committee 2009-2012 Scientific Review Committee, Cancer Prevention and Research Institute of Texas (CPRIT) 2010- Susan G. Komen for the Cure, Scientific Advisory Board 2011- Abramson Cancer Center of the University of Pennsylvania, External Scientific Advisory Board 2012 American Association for Cancer Research, Annual Meeting Program Committee, Co-chair 2014- Prostate Cancer Foundation Global Research Council

3 Myles A. Brown, M.D.

MEMBERSHIP IN PROFESSIONAL SOCIETIES: 1985 American Society of Microbiology, Member 1991 American Association for the Advancement of Science, Member 1995 American Association for Cancer Research, Member 1997 American Society for Clinical Investigation, Member 2002 Endocrine Society, Member 2003 Association of American Physicians, Member EDITORIAL BOARD:

1999-2001 Editorial Board, The Prostate Journal 2002-2006 Editorial Board, Molecular Endocrinology 2002- Senior Editor, Cancer Research

AWARDS AND HONORS:

1983 Helen Hay Whitney Foundation Fellowship 1988 Clinical Investigator Award, National Cancer Institute 1990 Emil Frei III Fellowship, Dana-Farber Cancer Institute 1992-1995 Claudia Adams Barr Investigator Award, Dana-Farber Cancer

Institute 1992-1996 American Cancer Society Award 1995,1996 CaP CURE Research Award 1995-1997 President, Boston Area Receptor Society 1996 Susan G. Komen Foundation Research Award 1997 American Society for Clinical Investigation

1999 Army Breast Cancer Program Academic Award 2003 Claudia Adams Barr Investigator Award, Dana-Farber Cancer

Institute 2003 Association of American Physicians 2005 NAMS/Wyeth Pharmaceuticals SERM Research Award 2006 2006 Tisch Family Outstanding Achievement Award 2006 Master of Arts, Honoris causa, Harvard University 2010 Edwin B. Astwood Award, The Endocrine Society

PART II: RESEARCH, TEACHING, AND CLINICAL CONTRIBUTIONS

A. Narrative report of Research, Teaching, and Clinical Contributions The primarily focus of the work in my laboratory at the Dana-Farber is the molecular understanding the mechanism of action of steroid hormone receptors including the estrogen and androgen receptors and their role in human cancer. We were the first to identify the p160 class of steroid receptor coactivators and to show that coregulators play an important role in the tissue and

4 Myles A. Brown, M.D.

promoter selective action of steroid hormone receptors and their ligands. This work has important implications for understanding the mechanism of action of selective estrogen receptor modulators or SERMs. More recently my lab was the first to define steroid receptor binding sites on a genome-wide scale using a combination of chromatin immunoprecipitation and tiled microarrays, ChIP-on-chip. In addition to work in my own laboratory, I am actively involved in the Breast and Prostate Cancer Programs at the DFCI. I am also actively involved in the teaching of post-doctoral fellows, graduate students and medical students. Together with Dr. James Decaprio, for many years I co-directed CDB211a "Biology of the Cancer Cell" at the Harvard Medical School. I was also a tutor in the "Genetics, Development, and Reproductive Biology” (and its predecessor) course for first year students at Harvard Medical School for many years. My clinical activities are limited at this point to attending on the in-patient Dana-Farber/Brigham and Women’s medical oncology service for 2-4 weeks per year and to following a very small number of general oncology patients in the out-patient clinics at the Dana-Farber. B. RESEARCH FUNDING INFORMATION: Past: 1988–1993 NCI K08 PI “Regulation of estrogen receptor expression.” 1993–1994 DFCI PI Butler Award Discretionary 1992-1995 DFCI: Barr Program Small Grant PI “Identification and cloning of ER-associated proteins.” 1992-1996 American Cancer Society Research Grant PI “Functions of estrogen receptor associated proteins.” 1992-1997 DFCI/Sandoz: Drug Discovery Program PI

“Discovery of ligands for new members of the nuclear receptor superfamily.”

1993-1995 Dept. of Public Health, Commonwealth of Massachusetts PI

“Transcriptional regulation of estrogen receptor in breast cancer.” 1994–1995 DFCI: Women’s Cancer Program PI “Estrogen Receptor” 1995–1999 CaP CURE Award PI “Mechanism of androgen receptor action in prostate cancer.” 1996-1997 Susan G. Komen Foundation Research Award PI

5 Myles A. Brown, M.D.

1996–2002 NCI/NIH: R01 CA57374 PI “Functions of estrogen receptor associated proteins.” 1998-2000 DFCI/Novartis: Drug Discovery Program PI

“Discovery of novel anti-androgens for the treatment of prostate cancer.”

1999-2002 DoD Army Breast Cancer Program Academic Award PI "Estrogen Receptor Signaling in Breast Cancer"

1999-2004 NCI/NIH: P01 CA80111 Sub:0002 PI “Estrogen signaling in breast development and cancer” Subproject 2 of “Mechanisms of breast development and carcinogenesis.” Robert Weinberg, PI

2000-2008 DFCI/Novartis: Drug Discovery Program PI “Discovery of novel steroid receptor ligands.”

2000-2005 NCI/NIH: P50 CA89393 Project 5 co-PI Dana-Farber/Harvard SPORE in Breast Cancer

2002-2006 DAMD17 02 1 0692 PI Army Breast Cancer Program Center of Excellence "Center for the Prevention and Treatment of ER-negative Breast Cancer"

2006-2007 NIDDK/NIH: R56 DK074967 PI

"Comprehensive Analysis of Estrogen Receptor Genomic Action"

2006-2008 Wyeth Pharmaceuticals, Sponsored research PI " Steroid Receptor Function in Osteoporosis"

2009-2010 DFCI/Novartis: Drug Discovery Program PI “Targeting ETS Factors and M-phase Genes in Prostate Cancer”

2005-2010 NCI/NIH: P50 CA89393-06 Project 3 Project co-PI "Role of Coregulators in Response to Aromatase Inhibitors" Dana-Farber/Harvard SPORE in Breast Cancer. J. Dirk Iglehart, PI 2008-2011 Prostate Cancer Foundation Co-Investigator "Synergistic targeting of AR and androgen synthesis in Prostate Cancer" Steven Balk, PI

6 Myles A. Brown, M.D.

Current

2007-2014 NIDDK/NIH: R01 DK074967-05 PI "Comprehensive analysis of estrogen receptor genomic action" 2012-2014 DFCI/Novartis: Drug Discovery Program PI

“Targeting steroid receptors and EZH2 in breast and prostate cancer” 2013-2018 NCI/NIH: P01 CA80111-15 Sub:0002 Project PI

“Epigenetics of hormone signaling in breast development and cancer” Subproject 2 of “Mechanisms of breast development and carcinogenesis” Robert Weinberg, PI

2013-2018 NCI/NIH: P50 CA168504-01A1 Sub:0001 Project co-PI “Androgens, androgen receptor signaling and breast carcinogenesis” Subproject 1 of “Dana-Farber/Harvard SPORE in breast cancer” Eric Winer, PI 2013-2018 NCI/NIH: P01 CA163227-01A1 Sub:0004 Project PI “Epigenetic reprogramming of AR function in CRPC” Subproject 4 of “Androgen receptor action in castration resistant prostate cancer” Steven Balk, PI 2013-2018 NCI/NIH: P50 CA090381-011 Sub:0004 Project co-PI "Targeting mechanisms driving AR activity in advanced CRPC" Subproject 4 of “Dana-Farber/Harvard SPORE in Prostate Cancer” Philip W. Kantoff, PI

2006-2016 NHGRI/NIH R01 HG004069-08 Co-Investigator "Computational Models of Mechanisms of Global Transcription Regulation" X. Shirley Liu, PI

C. REPORT OF TEACHING:

1. Local Contributions a. Medical School Courses 1992-1999 "Genetics, Embryology, and Reproduction” Harvard Medical School-

6 week course, Tutor for 8 medical students Preparation time-2 hrs/wk; Contact time-8 hrs 1995, 1997, CDB211a "Biology of the Cancer Cell" Harvard Medical School

7 Myles A. Brown, M.D.

1999, 2001 Course Co-Director and Lecturer for 26-40 graduate, dental, undergraduate students

Preparation time-2 hr/wk; Contact time-2 hr/wk; fall semester 2000 "Genetics, Development, and Reproductive Biology” Harvard

Medical School-6 week course Tutor for 8 medical students Preparation time-2 hrs/wk; Contact time-8 hrs b. Hospital courses and invited teaching presentations 1994 Epidemiology seminar, Harvard School of Public Health Lecturer for graduate students Preparation time-2 hrs; Contact time-1 hr 1995 Science and Breast Cancer Seminar Series, Massachusetts General

Hospital. “Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription.”

Lecturer for fellows, residents and medical students Preparation time-2 hrs; Contact time-1 hr 1995 Hematology/Oncology Research Seminar Series, Brigham and

Women’s Hospital. “Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription.”

Lecturer for fellows, residents and medical students Preparation time-2 hrs; Contact time-1 hr 1995 Harvard Center for Cancer Prevention Workshop: “Causes of

Cancer.” Lecturer for medical students, public health graduate students. Preparation time-2 hrs; Contact time-1 hr c. Teaching Leadership Role: 1991 Attending Physician, Adult Clinic, Dana-Farber Cancer Institute Trainees-fellows, residents d. Names of Advisees or Trainees:

1990-1997 Fei-hua Qiu, M.D., Ph.D., Staff Scientist, AtheroGenics, Alpharetta,

GA 1991-1993 Isabelle Treilleux, M.D., Assistant Professor of Pathology, Centre

Léon Bérard, Lyon, France. 1991-1996 Shlomit Halachmi, M.D., Ph.D., Dermatologist, Rabin Medical

Center, Petah Tikva, Israel

8 Myles A. Brown, M.D.

1992-1996 Adam Brufsky, M.D., Ph.D., Professor of Medicine, University of

Pittsburgh School of Medicine 1992-1997 Zuoqin Tang, M.D., Associate Physician, Department of Pathology,

San Francisco Medical Center 1994-1995 Rachel Meyers, Ph.D., Vice President, Research and RLD, Alnylam Pharmaceuticals, Cambridge, MA 1994-1997 Hong Liu, MD, Ph.D., Assistant Professor, Lurie Cancer Center,

Northwestern University, Chicago, IL

1995-1997 Bettina Hanstein, M.D., Universitats-Frauenklinik, Heinrich Heine Universitat, Dusseldorf, Germany

1995 –2000 David Chand, M.D., Infectious Disease Fellowship,

Rainbow Babies and Childrens Hospital, Cleveland, OH

1996–1998 Ramon Rivera-Gonzalez, Ph.D., Executive Director Plant Manager, Amgen, Puerto Rico

1996-2000 James DiRenzo, Ph.D., Associate Professor, Department of

Pharmacology, Dartmouth College of Medicine, Hanover, NH

1997-1998 Wongi Seol, Ph.D., Assistant Professor, Department of Biology, Sung Kyun Kwan University, Korea

1998–2000 Jaime Font de Mora, Ph.D., Team leader, Cellular and Molecular

Biology Laboratory, Spain 1999-2001 Yongfeng Shang, Ph.D., Professor and Chairman, Department of

Biochemistry, Peking University, Beijing, China 1999-2004 Wenlin Shao, Ph.D., Senior Investigator, Novartis, Cambridge, MA

1999-2010 Maria Torres-Arzayus, Ph.D., Instructor in Medicine, Dana-Farber

Cancer Institute and Harvard Medical School, Boston, MA 2000-2002 Eli Hestermann, Ph.D., Associate Professor, Department of Biology,

Furman University, Greenville, SC 2002-2006 Erika Keeton, Ph.D., Senior Scientist, AstraZeneca, Waltham, MA 2002-2006 Jason Carroll, Ph.D., Group Leader, Nuclear Receptor Transcription

Laboratory, Cambridge Research Institute, Cambridge, UK

9 Myles A. Brown, M.D.

2002-2007 Ania Szary, M.D., Radiology Resident, San Francisco General

Hospital, San Francisco, CA 2003-2010 Kirsten Fertuck, Ph.D., Adjunct Faculty, Department of Biology,

Boston College, Chestnut Hill, MA 2004-2008 Timothy Geistlinger, Ph.D., Staff Scientist, Amyris Biotechnologies,

Emeryville, CA 2004-2008 Susan Krum, Ph.D., Assistant Professor, UCLA School of Medicine,

Los Angeles, CA 2005-2008 Jérôme Eeckhoute, Ph.D., CNRS Staff Scientist, University of Rennes

1/CNRS Joint Research Unit 6026, Rennes, France 2004-2008 Qianben Wang, M.D., Ph.D., Associate Professor, Ohio State

University College of Medicine, Columbus, OH 2005-2008 Mathieu Lupien, Ph.D., Assistant Professor, Ontario Cancer Institute,

University of Toronto, Toronto, Canada 2008-2013 Housheng Hansen He, Ph.D., Assistant Professor, Ontario Cancer

Institute, University of Toronto, Toronto, Canada 2008-2013 Min Ni, Ph.D., Scientist, Infinity Pharmaceuticals, Cambridge, MA

Current Students: 2011- David Chi, Harvard Medical Student Current Postdocs:

2006- Jennifer Cook, Ph.D., Research Fellow in 2006- Gilles Buchwalter, Ph.D., Research Fellow in Medicine 2006- Shannon Bailey, Ph.D., Research Fellow in Medicine 2008- Luz Tavera-Mendoza, Ph.D., Research Fellow in Medicine 2008- Kexin Xu, Ph.D., Research Fellow in Medicine 2008- Thomas Westerling, Ph.D., Research Fellow in Medicine

10 Myles A. Brown, M.D.

2009- Laura Cato, Ph.D., Research Fellow in Medicine 2010- Hilary Wade, Ph.D., Research Fellow in Medicine 2011- Teng Fei, Ph.D., Research Fellow in Medicine

Regional, National or International Contributions

a. Invited presentations

1990 Biotechnology Process Engineering Center, Fifth Annual Symposium:

invited speaker, “Regulation of Gene Expression in Mammalian Cells.”

1993 FASEB Summer Research Conference: Cellular and Molecular

Genetics: invited speaker, “Estrogen receptor associated proteins.” 1995 Beth Israel Hospital Hematology/Oncology Grand Rounds, invited

speaker, “Estrogen receptor-associated proteins: possible mediators of hormone-induced transcription.”

1995 Molecular Biology and Biomolecular Engineering Seminar Series:

invited speaker, “Estrogen receptor-associated proteins.” 1995 Holyoke College, invited lecture, “Coactivators in Estrogen Receptor

Action.”

1996 AACR Annual Meeting: Symposium chairman, “Steroid Hormones: Breast and Prostate Cancer. Role of transcriptional coactivators in steroid receptor function.”

1996 Gordon Research Conference on Hormone Action: invited speaker,

“p300 is a component of an estrogen receptor coactivator complex.” 1997 Frontiers in Estrogen Action: Session chairman, “Steroid

Receptor Associated Proteins.”

1997 AACR Basic and Clinical Aspects of Breast Cancer: invited speaker, “Role of coactivators in estrogen receptor function.”

1997 Xth International Conference on Hormonal Steroids, Quebec City,

Canada invited speaker, “Convergence of coactivator pathways in steroid receptor signaling.”

11 Myles A. Brown, M.D.

1998 NIDDK Workshop on Co-Activators and Co-Repressor in Gene Expression: invited speaker, "Integration and Segregation in Steroid in Steroid Receptor Signaling."

1999 SERMs Symposium-Implications for Prevention and Treatment of Breast Cancer: invited speaker, "The Role of Co-Regulators in Modulating ER Selectivity."

2000 Indiana University Cancer Center Combined Seminar Series, invited speaker, “Dynamics of Estrogen Action.” 2000 Second International Symposium on the Molecular Biology of Breast

Cancer, Lillehammer, Norway, invited speaker, “The role of coactivators in oestrogen action.”

2000 Frontiers in Estrogen Action: Session chairman, “Steroid Receptor

Associated Proteins.” 2000 11th International Congress of Endocrinology, Sydney, Australia:

invited speaker, “Steroid receptor coactivators in cancer.” 2000 Hormones and Cancer 2000, Port Douglas, Australia, invited speaker,

“Dynamics of steroid receptor action.” 2001 Beth Israel Deaconess Medical Center, Boston, MA, invited speaker,

"Dynamics of Estrogen Action" 2001 AACR Annual Meeting, New Orleans, LA: invited speaker, "Role of

Coactivators in Cancer" 2001 NIH Endocrinology Grand Rounds, Bethesda, MD, invited speaker,

"Dynamics of Estrogen Receptor Action" 2001 Second International Conference on Newer Approaches to Androgen

Deprivation Thearpy (ADT) in Prostate Cancer, Cambridge, MA, invited speaker, "Estrogen Receptor: A Potential Target for Intervention?"

2002 AACR Annual Meeting, San Francisco, CA: invited speaker,

"Molecular Determinants of Nuclear Receptor Action." 2002 Keystone Symposium on Nuclear Receptors, Snowbird, UT: invited

speaker, "Molecular Determinants of SERM Specificity." 2002 Gordon Research Conference on Mammary Gland Biology, Il Ciocco,

Italy: invited speaker, "Dynamics of ER Signaling.”

12 Myles A. Brown, M.D.

2002 New York University School of Medicine Cancer Center Seminar,

invited speaker, “Co-regulators, SERMs and Cancer.” 2002 Lady Davis Institute, Montreal, Canada, invited speaker, "Co-

regulator Determinants of Estrogen Receptor Action." 2002 Endocrine Society Annual Meeting, San Francisco, CA: invited

speaker, "Coregulator Determinants of Steroid Receptor Action." 2002 Gordon Research Conference on Mechanism of Hormone Action,

invited speaker, "Mechanisms of estrogen receptor action" 2002 1st Annual Uterine Cancer Biology Symposium, Basic Biology and

Translational Opportunities in Prevention and Treatment, invited speaker, "Co-regulatory Determinants of Steroid Receptor Action"

2002 GlaxoSmithKline NR Symposium, invited speaker, “Molecular

Determinants of Nuclear Receptor Function.” 2002 Nutritional Genomics and Proteomics in Cancer Prevention

Conference, Bethesda, MD, invited speaker, "Molecular Determinants for the Tissue Specificity of SERMS"

2002 Dartmouth Medical School, Department of Pharmacology and

Toxicology Seminar, invited speaker, “Coregulators and Cancer.” 2002 Banbury Workshop on Glucocorticoid Regulatory Mechanisms and

Pathophysiology, Cold Spring Harbor, NY, invited participant 2003 University of Texas, Southwestern Department of Biochemistry

Seminar, invited speaker, “Molecular Determinants of Steroid Receptor Action.”

2003 Massachusetts General Hospital, Cutaneous Biology Research Center

Seminar, invited speaker, “Molecular Determinants of Nuclear Receptor Function.”

2003 The 2nd International Nuclear Receptor Meeting in Japan, Osaka,

Japan, invited speaker, “Coregulator determinants of steroid receptor function.”

2003 University of Alabama, Birmingham Department of Pharmacology

and Toxicology Seminar, invited speaker, “Coregulators and Cancer.”

13 Myles A. Brown, M.D.

2003 Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer, Cambridge, MA, invited speaker, “Molecular basis of action of SERMS and ER downregulators: diffences in coregulator funcitons.”

2003 Frontiers in Estrogen Action, invited speaker, “Molecular

Determinants of Estrogen Action.” 2003 AACR Special Conference, Advances in Breast Cancer Research:

Genetics, Biology, and Clinical Applications, Huntington Beach, CA, invited speaker, "Modulators of Steroid Receptor Action."

2003 Joseph and Mable Meites Lecture, Michigan State University,

“Coregulators and Cancer.”

2003 14th Annual George Khoury Memorial Lecture, The Wistar Institute, Philadelphia, PA, “Coregulators and Cancer."

2003 AstraZeneca 2003 Breast Cancer Symposium, Waltham, MA, invited

speaker, "Coactivators"

2004 The US-Japan Workshop on “The Role of Nuclear Receptors in Carcinogenesis”, Maui, HI, invited speaker, “Oncogenic Functions of a Steroid Receptor Coactivator.”

2004 Keystone Symposium, Nuclear Receptors: Steroid Sisters, Keystone,

CO, invited speaker, "Coactivator as Oncogene."

2004 Vanderbilt-Ingram Cancer Center Seminar Series, invited speaker, Nashville, TN, "New Functions for Steroid Receptor Coactivators."

2004 The University of Chicago Biomedical Sciences Cluster Committee

on Cancer Biology Seminar Series, Chicago, IL, invited speaker, "New Functions of a Steroid Receptor Coactivator."

2004 Yale Grand Rounds, The Julia and Patricia Kingsbury Lectureship, New Haven, CT, “Coregulators and Cancer.”

2004 The American Association for Cancer Research, Session Chairperson,

95th Annual Meeting, “Steroid Receptors and Their Relation to Risk and the Progression of Cancer.”

2004 The American Society of Andrology, 29th Annual Meeting, AUA

Lecture, “Selective Steroid Receptor Modulators.”

14 Myles A. Brown, M.D.

2004 The University of Texas M.D. Anderson Cancer Center, 57th Annual Symposium on Fundamental Cancer Research, Signal Transduction: From Pathways to Networks, invited speaker, "Convergence of Signaling Pathways in the Oncogenic Functions of a Steroid Receptor Co-activator."

2005 Sidney Kimmel Comprehensive Cancer Center, Special Symposium, Signal Transduction: from Development to Disease, invited speaker, Nuclear Receptors Signaling in Proliferation and Survival, “AIB1; from Coregulator to Oncogene.” 2005 Keystone Symposium, Hormonal Tumorigenesis, Monterey, CA Invited speaker, "Chromosome-scale Analysis of Steroid Hormone Action." 2005 Keystone Symposium, PPAR/LXR, Whistler, BC, Canada Invited speaker, "Chromosome-scale Analysis of Nuclear Receptor Action." 2005 2005 EGFR Summit, Boca Raton, FL, invited speaker, "AIB1 and IGF: A link between growth factor and estrogen signaling." 2005 University of Cincinnati Cancer Center, invited speaker, "Chromatin Dynamics and chromosome-scale analysis of steroid receptor action." 2005 Gordon Conference, Hormone Action in Development & Cancer, Mount Holyoke College, South Hadley, MA, invited speaker, "Mammary tumors and PI3K/AKT pathway activation in AIB1 transgenic mice" 2005 Brigham and Women's Hospital Endocrine Grand Rounds, Boston, MA, invited speaker, "Chromatin dynamics and chromosome-scale analysis of steroid receptor action." 2006 Indiana University School of Medicine Seminar Series, Indianapolis, IN, invited speaker, "Genome-wide analysis of steroid receptor function." 2006 NCI CCR Grand Rounds, Bethesda, MD, invited speaker, "Genome- wide analysis of steroid hormone action." 2006 Keystone Symposium, Nuclear receptors: steroid sisters, Banff, Alberta, Canada, invited speaker, "Genome-wide analysis of steroid receptor function."

15 Myles A. Brown, M.D.

2006 ENDO 2006, 88th Annual Meeting of the Endocrine Society, Boston, MA, invited speaker, "Genome-wide Analysis of Steroid Hormone Action." 2006 Nuclear Receptors 2006, Karolinska Institutet, Stockholm, Sweden, invited speaker, "Defining the Steroid Receptor Cistrome." 2006 Androgens 2006, Queens College, Cambridge, UK, invited speaker, "Genome-wide analysis of androgen action." 2006 CSHL Meeting, Nuclear Receptors: Bench to Bedside, Cold Spring Harbor, NY, invited speaker, "Defining the Nuclear Receptor Cistrome." 2007 First ROC International Workshop and Practical Course on

Chromatin Immunoprecipitation Related Techniques, Rome Oncogenomic Center, Rome, Italy, invited speaker, "Defining the Steroid Receptor Cistrome."

2007 4th International Nuclear Receptor Meeting in Japan, Osaka, Japan, invited speaker, "Defining the Nuclear Receptor Cistrome." 2007 AACR Annual Meeting, Los Angeles, CA, invited speaker,

"Hormone Action on the Genomic Scale: Defining the Nuclear Receptor Cistrome."

2007 EMBO Conference, Nuclear Receptors in Health and Disease,

Gardone Riviera, Italy, invited speaker, "Defining the NR Cistrome: Genome-Wide Identification of Nuclear Receptor Targets."

2007 Gordon Research Conference, Epithelial Differentiation &

Keratinization, Bryant University, Smithfield, RI, invited speaker, "Deciphering the Enhancer Code."

2007 CSHL Meeting, Mechanisms of Eukaryotic Transcription, Cold

Spring Harbor, NY, invited speaker, "FoxA1 Translates Epigenetic Signatures into Cell-Specific Transcriptional Programs."

2007 AACR Special Conference, Advances in Breast Cancer Research,

San Diego, CA, invited speaker, "Deciphering the Transcriptional Regulatory Networks in Breast Cancer."

2008 Keystone Symposium, Forkhead Transcription Factor Networks in

Development, Signaling, and Disease, Midway, UT, Keynote Speaker, "Connecting Forkhead Factors and Nuclear Receptors to the Genome."

16 Myles A. Brown, M.D.

2008 Keystone Symposium, Orphan Brothers/Steroid Sisters, Whistler,

BC, Canada, "Defining the Nuclear Receptor Cistrome." 2008 11th Frontiers in Nuclear Receptor Action, Savannah, GA, invited speaker, "FoxA1 Translates Epigenetic Signatures into Lineage- Specific Transcription Mediated by Steroid Hormone Receptors." 2008 Biomedicum Helsinki Seminar, Helsinki, Finland, invited speaker, "Defining the Nuclear Receptor Cistrome." 2008 Second JCA-AACR Special Joint Conference, The Latest Advances in Breast Cancer Research from Basic Science to Therapeutics, Hyogo, Japan, invited speaker, "Deciphering Transcriptional Regulatory Networks in Breast Cancer." 2008 CSHL Meeting, Nuclear Receptors: Bench to Bedside, Cold Spring Harbor, NY, invited speaker, "Reprogrammed Androgen Receptor Drives the Growth of Androgen-independent Prostate Cancer" 2008 Nobel Conference No 52, Recent Advances in Understanding Estrogen Signaling: From Molecular Insights to Clinical Implications, Sånga Säby, Sweden, invited speaker, "Refining the ERα Cistrome" 2008 International Congress on Hormonal Steroids and Hormones and Cancer, Quebec City, Canada, invited speaker, "Unraveling Steroid Receptor Cistromes"

2008 University of Louisville School of Medicine, Center for Genetics and Molecular Medicine Seminar, Louisville, KY, invited speaker, "Nuclear Receptor Cistromes" 2008 Roswell Park Cancer Center Seminar, Buffalo, NY, invited speaker, "Reprogramming of Androgen Receptor Function in Androgen Independent Prostate Cancer" 2009 NIH Transcription Factor Interest Group Seminar, Bethesda, MD, invited speaker, "Reprogrammed Androgen Receptor Function in Androgen-Independent Prostate Cancer"

2009 Primary Therapy of Early Breast Cancer, 11th International Conference, St. Gallen, Switzerland, invited speaker, "Mining the Steroid Receptor Cistrome for Novel Targets, Biomarkers, and Risk Alleles"

17 Myles A. Brown, M.D.

2009 Memorial Sloan Kettering Cancer Center Presidential Seminar Series, D. Wayne Calloway Visiting Lectureship in Prostate Cancer, "Reprogrammed Androgen Receptor Function in Androgen Independent Prostate Cancer" 2009 Estrogens, SERMs, TSECs Meeting, Fort Myers, FL, invited speaker "Cistromes View of ER/PR Action" 2009 Hot Topics in Translational Oncology, Hereditary Breast And Ovarian Cancer, Catanzaro, Italy, invited speaker, "Mining the Steroid Receptor Cistrome for Novel Targets, Biomarkers, and Risk Alleles" 2009 Gordon Research Conference, Hormone Action in Development and Cancer, Plymouth, NH, invited speaker, "A Cistromes View of Hormone Dependence" 2009 12th International Conference on Differentiation Therapy and Innovative Therapeutics in Oncology, Chicago, IL, invited speaker, “Epigenetics and Cistromics of Steroid Receptors in Cancer” 2010 Georgetown University School of Medicine, invited speaker, "Epigenomics and Cistromics of Hormone Dependent Cancer" 2010 University of Pennsylvania School of Medicine, Institute for Diabetes, Obesity & Metabolism Seminar Series, invited speaker, "Cistromics and Epigenomics of Hormone Action" 2010 Ohio State University Comprehensive Cancer Center, Monthly Molecular Biology and Cancer Genetics Meeting, invited speaker, "Epigenomics and Cistromics of Hormone Dependent Cancer" 2010 Keystone Symposium, Nuclear Receptors: Signaling, Gene Regulation and Cancer, Keystone, CO, organizer and invited speaker, “Nuclear Receptor Cistromes and Epigenomes” 2010 AACR Annual Meeting, Washington, DC, Educational Session, invited speaker, "Epigenomics and Cistromics of Hormone Dependent Cancers"

2010 Dana-Farber Harvard Cancer Center, Nuclear Dynamics and Cancer Symposium, invited speaker, “Hormone Dependent Cancers: Genomes to Cistromes” 2010 Estrogens, SERMs, TSECs Scientific Meeting, Philadelphia, PA, invited speaker, "Epigenomics of Hormone Action"

18 Myles A. Brown, M.D.

2010 Third Annual Dartmouth Integrative Biology Symposium, Clinical & Translational Science, Dartmouth College, Hanover, NH, Keynote Speaker, “Epigenomics and Cistromics of Hormone Dependent Cancer” 2010 Masonic Cancer Center Seminar, University of Minnesota, Minneapolis, MN, invited speaker, “Epigenomics and cistromics of hormone dependent cancers” 2010 ENDO 2010: The 92nd Annual Meeting of the Endocrine Society, Edwin B. Astwood Award Lecture, “Steroid Hormone Action From Genome to Cistrome” 2010 Society for the Study of Reproduction, 43rd Annual Meeting, Milwaukee, WI, State of the Art Lecture, “Cistromes Approach to Hormone Action” 2010 CSHL Meeting, Nuclear Receptors & Disease, Cold Spring Harbor, NY, invited speaker, "Growth Regulation by AR in ER- negative Breast Cancer" 2010 UCLA Molecular Biology Institute Interdepartmental Seminar Series, Los Angeles, CA, invited speaker, “A Cistromes Approach to Hormone Action” 2010 American Society for Cell Biology 50th Annual Meeting, Philadelphia, PA, invited speaker, "Epigenetics and Cistromics of Hormone Dependent Cancers" 2011 Baylor College of Medicine, Dan L. Duncan Cancer Center and Translational Biology & Molecular Medicine Joint Seminar, Houston, TX, invited speaker, “Functional Epigenetics of Hormone Dependent Cancers” 2011 Estrogens, SERMs, TSECs Scientific Meeting, Clearwater, FL, invited speaker, “Epigenetic and Chromatin Dynamics of Steroid Receptor Function” 2011 Roswell Park Cancer Center Seminar, Buffalo, NY, invited speaker, “Epigenetic Programs of Hormone Dependence” 2011 6th Biennial SCCPIR Research Meeting, Chicago, IL, Keynote Speaker, “Epigenetic and Chromatin Dynamics of Steroid Receptor Function”

19 Myles A. Brown, M.D.

2011 H Foundation Symposium, Lurie Cancer Center, Northwestern University, Chicago, IL, invited speaker, “Epigenetic Reprogramming in Cancer” 2011 Tulane Cancer Center/ Louisiana Cancer Research Consortium Seminar Series, New Orleans, LA, invited speaker, “Epigenetics and Chromatin Dynamics of Hormone Dependent Cancers” 2011 EMBO Conference, Nuclear Receptors: From Molecular Mechanism to Health and Disease, Sitges, Barcelona, Spain, invited speaker, “Epigenetic reprogramming of hormone action.” 2011 AACR Special Conference, Advances in Breast Cancer Research: Genetics, Biology, and Clinical Applications, San Francisco, CA, invited speaker, “Epigenetic and cistromic determinants of endocrine dependence.” 2011 2011 Tongji-Novartis Cancer and Epigenetics Symposium, Shanghai, China, keynote speaker, “Epigenetics of Hormone Dependent Cancers.” 2011 CTRC-AACR San Antonio Breast Cancer Symposium, San Antonio, TX, invited speaker, “Steroid receptor cistromics.” 2011 AACR International Conference on New Horizons in Cancer Research: Biology to Prevention to Therapy, Gurgaon, Delhi (NCR), India, invited speaker, “Epigenetics of hormone dependence.” 2012 MCRI Molecular Medicine Seminar Series, Tufts Medical Center, Boston, MA, invited speaker, “Epigenetics of hormone dependence.” 2012 AACR Special Conference, Advances in Prostate Cancer Research, Orlando, FL, keynote speaker, “Polycomb dependent and independent functions of EZH2 in prostate cancer.” 2012 University of Chicago, Committee on Cancer Biology Seminar Series, invited speaker, “Epigenetics of hormone dependence.” 2012 AACR Annual Meeting, Chicago, IL, The Ruth Sager Memorial Symposium on Cancer Genetics and Epigenetics: Chromatin, Transcriptional Regulation, and Cancer, invited speaker, “Epigenetic and cistromic reprogramming of hormone dependence.” 2012 AACR Annual Meeting, Chicago, IL, Forum: Epigenetics or Epiphenomenon, moderator

20 Myles A. Brown, M.D.

2012 3ème Journee Scientifique Roger Monier, Institut de Cancérologie Gustave-Roussy, Villejuif, France, invited speaker, “Epigenetic reprogramming of hormone action.” 2012 Boston Area Gene Expression meeting, Tufts University, Boston,

MA, invited speaker, “Polycomb independent function of EZH2 in castration resistant prostate cancer”

2012 Prostate Cancer Foundation, 19th Annual Scientific Retreat, Carlsbad,

CA, special lecture, “EZH2 oncogenic function in CRPC is polycomb independent”

2013 Cardinal Bernardin Cancer Center's Basic Science Seminar Series at

Loyola University, Chicago, IL, invited speaker, “Epigenomics of hormone dependent cancers”

2013 CSHL Meeting, Cancer Biology & Therapeutics, Cold Spring Harbor, NY, invited speaker, "Targeting EZH2 in castration resistant prostate cancer" 2013 Mount Sinai School of Medicine, Department of Oncological

Sciences Seminar, New York, NY, invited speaker, “Epigenomics of hormone dependent cancers”

2013 Medical University of South Carolina, Hollings Cancer Center

Seminar, Charleston, SC, invited speaker, “Epigenomics of hormone dependent cancers”

2013 Society for Basic Urologic Oncology/Society of Urologic Oncology

Joint Session at the American Urologic Association Annual Meeting, San Diego, CA, invited speaker, “Targeting EZH2 in castration-resistant prostate cancer”

2013 University of Massachusetts School of Medicine, Program in Systems

Biology Seminar, Worcester, MA, invited speaker, “Epigenomics of hormone dependent cancers”

2013 Estrogens, SERMs, TSECs Scientific Meeting, Clearwater, FL, invited speaker, “Epigenomics and cistromics of the actions of BZA and CEE”, sponsored by Pfizer 2013 AACR Special Conference, Chromatin and Epigenetics in Cancer, Atlanta, GA, invited speaker, “Epigenetics of hormone dependence”

21 Myles A. Brown, M.D.

2013 Flemish Training Network Life Sciences (FTNLS) symposium, The Epigenetics Revolution, Leuven, Belgium, invited speaker, “Epigenomics of hormone dependent cancer” 2013 FEBS Advanced Lecture Course, Spetses Summer School on Nuclear Receptor Signaling in Physiology and Disease, Island of Spetses, Greece, IUMB Keynote Speaker, “Epigenetics of nuclear receptor function in cancer” 2013 University of Wisconsin, McArdle Seminar in Cancer Biology, Madison, WI, invited speaker, “Epigenomics of hormone dependent cancers” 2013 University of Pittsburgh School of Medicine, Pittsburgh Area Nuclear Receptor Club, Pittsburgh, PA, keynote speaker, “Epigenetics of nuclear receptor function” 2013 Duke Medical School, Regulatory Networks in Health and Disease seminar, Durham, NC, invited speaker “Epigenetics of nuclear receptor function” 2013 Prostate Cancer Foundation, 20th Annual Scientific Retreat, National Harbor, MD, invited speaker, “Targeting Epigenetic Regulators in Prostate Cancer” 2013 Vanderbilt-Ingram Cancer Center Seminar Series, Nashville, TN, invited speaker, “Epigenetics and Genetics of Hormone Dependent Cancers” 2013 Wake Forest University, Annual Students’ Distinguished Seminar, Winston-Salem, NC, invited speaker, “Genetics and Epigenetics of Hormone Dependence” 2014 Keystone Symposium, Nuclear Receptors: Biological Networks,

Genome Dynamics and Disease, Taos, NM, invited speaker, “Targeting EZH2 in Castration Resistant Prostate Cancer”

2014 AACR Special Conference, Advances in Prostate Cancer Research,

San Diego, CA, invited speaker, “Epigenetic Targets in Castration Resistant Prostate Cancer”

2014 AACR Annual Meeting, San Diego, CA, invited speaker, Major

Symposium: Functional Regulation of the Cancer Genome, “Genetic and Epigenetic Mechanisms of Resistance to Endocrine Therapy”

22 Myles A. Brown, M.D.

2014 International Symposium on Medical Epigenetics, Freiburg, Germany, invited speaker, “Epigenetic and Genetic Determinants of Hormone Dependence”

2014 Estrogens, SERMs, TSECs Scientific Meeting, Clearwater, FL, invited speaker, “Epigenomics of TSEC Action in Cynomolgus Monkeys”, sponsored by Pfizer 2014 Gordon Research Conference, Mammary Gland Biology, Lucca (Barga), Italy, invited speaker, “Epigenomics of Hormone Signaling”

23 Myles A. Brown, M.D.

PART III: BIBLIOGRAPHY Original Articles: 1. Khoury G, Howley P, Brown M, Martin MA. The detection and quantitation of SV40

nucleic acid sequences using single stranded DNA probes. Cold Spring Harbor Symposium on Quantitative Biology 1975; 39:147-52.

2. Khoury G, Carter B, Ferdinand FJ, Howley P, Brown M, Martin MA. Genome localization

of simian virus 40 RNA species. J Virol 1976;17:832–40. 3. Rosenthal L, Brown M. The control of SV40 transcription during a lytic infection: late

RNA synthesis in the presence of inhibitors of DNA replication. Nucleic Acids Res 1977;4:551–6.

4. Ferdinand FJ, Brown M, Khoury G. Synthesis and characterization of late lytic SV40 RNA

from transcriptional complexes. Virology 1977;78:150–61. 5. Kuster JM, Mora PT, Brown M, Khoury G. Immunologic selection against SV40

transformed cells: concomitant loss of viral antigens and early viral gene sequences. Proc Natl Acad Sci (USA) 1977;74:4796–800.

6. Ferdinand FJ, Brown M, Khoury G. Characterization of early SV40 transcriptional

complexes: late transcription in the absence of detectable DNA replication. Proc Natl Acad Sci (USA) 1977;74:5443–7.

7. Goldman N, Brown M, Khoury G. Modification of SV40 T-antigen by poly ADP-

ribosylation. Cell 1981;24:567–72. 8. Lynch DC, Zimmerman TS, Collins CJ, Brown M, Morin MJ, Ling EH, Livingston DM.

Molecular cloning of cDNA for human von Willebrand factor: authentication by a new method. Cell 1985;41:49–56.

9. Brown M, McCormack M, Zinn KG, Farrell MP, Bikel I, Livingston DM. A recombinant

murine retrovirus for SV40 large T cDNA transforms mouse fibroblasts to anchorage independent growth. J Virol 1986;60:290–3.

10. Bikel I, Montano X, Agha, ME, Brown M, McCormack M, Boltax J, Livingston DM. SV40

small t antigen enhances the transformation activity of limiting concentrations of SV40 large T antigen. Cell 1987;48:321–30.

11. Brown M, Figge J, Hansen U, Wright C, Jeang KT, Khoury G, Livingston DM, Roberts TM.

Lac repressor can regulate expression from a hybrid SV40 early promoter containing a lac operator in animal cells. Cell 1987;49:603–12.

24 Myles A. Brown, M.D.

12. Cherington V, Brown M, Paucha E, St. Louis J, Spiegelman BM, Roberts TM. Separating SV40 large T antigens transforming function from the ability to block differentiation. Mol Cell Biol 1988;8:1380–4.

13. Brown M, Sharp PA. Human estrogen receptor forms multiple protein-DNA complexes. J

Biol Chem 1990;265:11238–43. 14. Kjems J, Brown M, Chang DD, Sharp PA. Structural analysis of the interaction between the

human immunodeficiency virus Rev protein and the Rev response element. Proc Natl Acad Sci (USA) 1990;88:683–7.

15. Segars JH, Marks MS, Hirschfeld S, Driggers PH, Martinez E, Grippo JF, Brown M,

Wahli W, Ozato K. Inhibition of estrogen-responsive gene activation by the retinoid X receptor B: Evidence for multiple inhibitory pathways. Mol Cell Biol 1993;13:2258–68 (author correction, vol. 15, p 3840).

16. Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C, Brown M. Estrogen receptor

associated proteins: possible mediators of hormone-induced transcription. Science 1994; 264:1455–8.

17. Yu K, Bayona W, Kallen CB, Harding HP, Ravera CP, McMahon G, Brown M, Lazar MA.

Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 1995;270:23975–83.

18. Kurokawa R, Söderström M, Hörlein A, Halachmi S, Brown M, Rosenfeld MG, Glass CK.

Polarity-specific activities of retinoic acid receptors determined by a co-repressor. Nature 1995; 377:451–4.

19. Scully R, Ganesan S, Brown M, De Caprio JA, Cannistra SA, Feunteun J, Schnitt S,

Livingston DM. Location of BRCA1 in human breast and ovarian cancer cells. Science 1996;272:123–5.

20. Hanstein B, Eckner R, DiRenzo J, Halachmi S, Liu H, Searcy B, Brown M. p300 is a

component of an estrogen receptor co-activator complex. Proc Natl Acad Sci 1996;93:11540-5

21. Giovannucci E, Stampfer MJ, Krithivas K, Brown M, Brufsky A, Talcott J, Hennekens CH,

Kantoff PW. The CAG repeat within the androgen receptor and prostate cancer progression. Proc Natl Acad Sci 1997;94:3320-3323.

22. Tang Z, Treilleux I, Brown M. A transcriptional enhancer required for the differential

expression of the human estrogen receptor in breast cancer. Mol Cell Biol 1997;17:1274-1280.

23. Kantoff PW, Febbo PG, Giovannucci E, Krithivas K, Dahl DM, Chang G, Hennekens CH,

Brown M, Stampfer MJ. A polymorphism of the 5 alpha-reductase gene and its association

25 Myles A. Brown, M.D.

with prostate cancer: a case-control analysis. Cancer Epidemiol Biomarkers Preven 1997;6:189-92.

24. Treilleux I, Peloux N, Brown M, Seargeant A. Human estrogen receptor gene promoter P1:

estradiol independent activity and estradiol inducibility in ER+ and ER- cells. Mol Endocrinol 1997;11:1319-31.

25. Neuman E, Ladha MH, Lin N, Upton TM, Miller SJ, DiRenzo J, Pestell RG, Hinds PW,

Dowdy SF, Brown M, Ewen ME. Cyclin D1 stimulation of estrogen receptor transcription independent of Cdk4 activation. Mol Cell Biol 1997;17:5338-47.

26. Platz E, Giovannucci E, Dahl D, Krithivas K, Brown M, Hennekens C, Stampfer M, Kantoff

PW. The GGN repeat in the androgen receptor and prostate cancer risk. Cancer Epidemiol Biomarkers Prev. 1998;7:379-84.

27. Seol W, Hanstein B, Brown M, Moore DD. Inhibition of estrogen receptor action by the

orphan receptor SHP. Mol Endocrinol 1998;12(10):1551-7. 28. Febbo PG, Kantoff PW, Giovannucci E, Brown M, Chang G, Hennekens CH, Stampfer M.

Debrisoquine hydroxylase (CYP2D6) and prostate cancer. Cancer Epidemiol Biomarkers Prev. 1998;7:1075-8.

29. Shim W-S, DiRenzo J, DeCaprio JA, Santen RJ, Brown M, Jeng M-H. Segregation of

steroid receptor coactivator-1 from steroid receptors in mammary epithelium. Proc Natl Acad Sci 1999;96:208-13.

30. Hanstein B, Liu H, Yancisin M, DiRenzo J, Brown M. Functional analysis of a novel

estrogen receptor beta isoform. Mol Endocrinol 1999;13:129-37. 31. Rebbeck TR, Kantoff PW, Krithivas K, Blackwood MA, Godwin AK, Daly MB, Narod SA,

Garber JE, Lynch HT, Weber BL, Brown M. Modification of BRCA1-associated breast cancer penetrance by the polymorphic androgen receptor CAG repeat. Am J Hum Genet 1999;64:1371-77.

32. Krithivas K, Yurgalevitch S, Mohr B, Wilcox C, Batter S, Brown M, Longcope C,

McKinlay J, Kantoff PW. Evidence that the CAG repeat in the androgen receptor gene is associated with the age related decline in serum androgen levels in men. Endocrinology 1999;162:137-42.

33. Platz E, Giovannucci E, Brown M, Cieluch C, Shepard T, Stampfer M, Kantoff P.

Amplified in breast cancer-1 glutamine repeat and prostate cancer risk. The Prostate Journal 2000;2: 27-32.

34. Poelzl G, Kasai Y, Mochizuki N, Shaul PW, Brown M, Mendelsohn ME. Specific

association of estrogen receptor beta with the cell cycle spindle assembly checkpoint protein, MAD2. Proc Natl Acad Sci U S A. 2000;97:2836-39.

26 Myles A. Brown, M.D.

35. Jones GB, Wright JM, Hynd G, Wyatt JK, Yancisin M, Brown M. Library screening allows

rapid identification of bioactive enediynes. Org Lett 2000;2:1863-66. 36. Font de Mora, J, Brown, M. AIB1 is a conduit for kinase-mediated growth factor signaling

to the estrogen receptor. Mol Cell Biol 2000;20:5041-47. 37. Haiman CA, Hankinson SE, Spiegelman D, Colditz GA, Willett WC, Speizer FE, Brown M,

Hunter DJ. A polymorphic repeat in AIB1 does not alter breast cancer risk. Breast Cancer Res 2000;19:378-85.

38. Carroll, RS, Brown, M, Zhang, J, DiRenzo, J, Font de Mora, J, Black, PM. Expression of a

subset of steroid receptor cofactors is associated with progesterone receptor expression in meningiomas. Clin Cancer Res 2000;6:3570-75.

39. DiRenzo, J, Shang, Y, Phalen, M, Sif, S, Myers, M, Kingston, R, Brown, M. BRG-1 is

recruited to estrogen-responsive promoters and cooperates with factors involved in histone acetylation. Mol Cell Biol 2000;20: 7541-49.

40. Shang Y, Hu X, Lazar MA, DiRenzo, J, Brown M. Cofactor dynamics and sufficiency in

estrogen receptor regulated transcription. Cell 2000;103:843-52. 41. Planas-Silva MD, Shang Y, Donaher JL, Brown M, Weinberg RA. AIB1 enhances estrogen-

dependent induction of cyclin D1 expression. Cancer Res 2001;61:3858-62. 42. Jones GB, Hynd G, Wright JM, Purohit A, Plourde II GW, Huber RS, Mathews JE, Li A,

Kilgore MW, Bubley GJ, Yancisin M, Brown M. Target-directed enediynes: designed estramycins. J Org Chem 2001;66:3688-95.

43. Rebbeck TR, Wang Y, Kantoff PW, Krithivas K, Neuhausen S, Godwin AK, Daly MB,

Narod SA, Brunet J-S, Vesprini D, Garber JE, Lynch HT, Weber BL, Brown M. Modification of BRCA1- and BRCA2-associated breast cancer risk by AIB1 genotype and reproductive history. Cancer Res. 2001;61:5420-24.

44. Yahata T, Shao W, Endoh H, Hur J, Coser KR, Sun H, Ueda Y, Kato S, Isselbacher KJ,

Brown M, Shioda T. Selective coactivation of estrogen-dependent transcription by CITED1 CBP/p300-binidng protein. Genes Dev. 2001;15:2598-2612.

45. DiRenzo J, Signoretti S, Nakamura N, Rivera-Gonzalez R, Sellers WR, Loda M, Brown M.

Growth factor requirements and basal phenotype of an immortalized mammary epithelial cell line. Cancer Res 2002;62:89-98.

46. Haiman CA, Brown M, Hankinson SE, Speigelman D, Colditz GA, Willett WC, Kantoff

PW, Hunter DJ. The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses’ Health Study. Cancer Res 2002;62:1045-49.

27 Myles A. Brown, M.D.

47. Haiman CA, Hankinson SE, Spiegelman D, Brown M, Hunter DJ. No association between a single nucleotide polymorphism in CYP19 and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2002;11:215-6.

48. Shang, Y, Myers M, Brown M. Formation of the androgen receptor transcription complex.

Mol Cell 2002;9:601-10. 49. Shang Y, Brown M. Molecular determinants for the tissue specificity of SERMs. Science

2002; 295(5564):2465-8. 50. Shao W, Halachmi S, Brown M. ERAP140, a conserved tissue-specific nuclear receptor

coactivator. Mol Cell Biol 2002;22:3358-72. 51. Hestermann E and Brown M. Agonist and chemopreventative ligands induce differential

transcriptional cofactor recruitment by aryl hydrocarbon receptor. Mol Cell Biol 2003;23:7920-25.

52. Shao W, Keeton EK, McDonnell DP, Brown M. Coactivator AIB1 links estrogen receptor

transcriptional activity and stability. Proc Natl Acad Sci U S A. 2004;101:11599-604. 53. Torres-Arzayus MI, Font de Mora J, Yuan J, Vazquez F, Bronson R, Rue M, Sellers WR,

Brown M. High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene. Cancer Cell 2004;6:263-74.

54. Febbo PG, Lowenberg M, Thorner AR, Brown M, Loda M, and Golub TR. Androgen

mediated regulation and functional implications of fkbp51 expression in prostate cancer. J Urol 2005;173:1772-77.

55. Keeton EK, and Brown M. Cell Cycle Progression Stimulated by Tamoxifen-bound ERα

and Promoter-Specific Effects in Breast Cancer Cells Deficient in the Corepressors N-CoR and SMRT. Mol Endocrinol 2005;19:1543-54.

56. Carroll JS, Liu XS, Brodsky AS, Meyer CA, Li W, Szary AJ, Eeckhoute J, Shao W,

Hestermann EV, Geistlinger TR, Fox EA, Silver PA, Brown M. Chromosome-wide Mapping of Estrogen Receptor Binding Reveals Long-range Regulation Requiring the Forkhead Protein FoxA1. Cell 2005; 15;122:33-43.

57. Georgescu S, Karas R, Qing L, Li JH, Galper J, Brown M. Mendelsohn ME. Modulator

Recognition Factor 1 (MRF1), an ARID-Family Member, is a Novel Co-Repressor for Estrogen Receptor α. Mol Endocrinol 2005; 19:2491-501. [Epub 2005 Jun 7].

58. Wang Q, Carroll JS and Brown M. Spatial and temporal recruitment of androgen receptor

and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell, 19: 631-642, 2005.

28 Myles A. Brown, M.D.

59. Colilla S, Kantoff PW, Neuhausen SL, Godwin AK, Daly MB, Narod SA, Garber JE, Lynch HT, Brown M, Weber BL, Rebbeck TR. The joint effect of smoking and AIB1 on breast cancer risk in BRCA1 mutation carriers. Carcinogenesis 2006; 27:599-605.

60. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A, Liao X, Iglehart JD,

Livingston DM, Ganesan S. X-chromosomal abnormalities in basal-like human breast cancer. Cancer Cell 2006; 9:121-32.

61. Carroll DK, Carroll JS, Leong CO, Cheng F, Brown M, Mills AA, Brugge JS and Ellisen

LW. p63 regulates an adhesion programme and cell survival in epithelial cells. Nat Cell Biol, 8: 551-561, 2006.

62. Johnson WE, Li W, Meyer CA, Gottardo R, Carroll JS, Brown M and Liu XS. Model-based

analysis of tiling-arrays for ChIP-chip. Proc Natl Acad Sci U S A, 103: 12457-12462, 2006. 63. Eeckhoute, J, Carroll JS, Geistlinger TR, Torres-Arzayus MI, Brown M. A cell-type specific

transcriptional network required for estrogen regulation of cyclin D1 and cell cycle progression in breast cancer. Genes Dev,15;20(18):2513-26, 2006.

64. Wang QF, Prabhakar S, Wang Q, Moses A, Chanan S, Brown M, Eisen M, Cheng JF, Rubin

E and Boffelli D. Primate-Specific Evolution of an LDLR Enhancer. Genome Biol, 7: R68, 2006.

65. Carroll JS, Meyer CA, Song J, Li W, Geistlinger TR, Eeckhoute J, Brodsky AS, Keeton EK,

Fertuck KC, Hall GF, Wang Q, Berkiranov S, Sementchenko V, Fox EA, Silver PA, Gingeras TR, Liu XS, Brown M. Genome wide analysis of estrogen receptor binding sites. Nat Genet. 2006 Nov; 38:1289-97. Epub 2006 Oct 1.

66. Torres-Arzayus MI, Yuan J, DellaGatta JL, Lane H, Kung AL, and Brown M. Targeting the

AIB1 oncogene through mTOR inhibition in the mammary gland. Cancer Res, 2006 Dec 1;66(23):11381-8.

67. Durand M, Kolpak A, Farrell T, Elliott NA, Shao W, Brown M and Volkert MR. The OXR

domain defines a conserved family of eukaryotic oxidation resistance proteins. BMC Cell Biology 2007 Mar 28;8:13.

68. Eeckhoute J, Keeton EK, Lupien M, Krum SA, Carroll JS, Brown M. A positive cross-

regulatory loop ties GATA-3 to estrogen receptor α expression in breast cancer. Cancer Res 2007 Jul 1;67(13):6477-83.

69. Wang Q, Li W, Liu XS, Carroll JS, Jänne OA, Keeton EK, Chinnaiyan AM, Pienta KJ and

Brown M. A hierarchical network of transcription factors governs androgen receptor dependent prostate cancer growth. Mol Cell 2007;27(3):380-92.

70. Frietze S, Lupien M, Silver PA and Brown M. CARM1 regulates estrogen stimulated breast

cancer growth through the regulation of E2F1. Cancer Res 2008 Jan 1;68(1):301-6.

29 Myles A. Brown, M.D.

71. Krum SA, Miranda-Carboni GA, Hauschka PV, Carroll JS, Lane TF, Freedman LP and

Brown M. Estrogen protects bone by inducing Fas ligand in osteoblasts to regulate osteoclast survival. EMBO J 2008 Feb 6;27(3):535-45.

72. Johnson DS, Li W, Gordon DB, Bhattacharjee A, Curry B, Ghosh J, Bizuela L, Carroll JS,

Brown M, Flicek P, Koch C, Dunham I, Bieda M, Xu X, Farnham PJ, Kapranov P, Nix DA, Gingeras T, Zhang X, Holster H, Jing N, Green R, Song J, McCuine SA, Anton E, Nguyen L, Trinklen ND, Ye Z, Ching K, Hawkins D, Ren B, Scacheri PC, Rozowsky J, Kaprikov A, Euskirchen G, Weissman S, Gerstein M, Snyder M, Yang A, Moqtaderi Z, Hirsch H, Shulha, HP, Fu Y, Weng Z, Struhl K, Myers RM, Lieb JD, Liu XS. Systematic evaluation of variability in simulated ChIP-chip experiments. Genome Res 2008 Mar;18(3):393-403.

73. Bao BY, Chuang BF, Wang Q, Sartor O, Balk SP, Brown M, Kantoff PW, Lee G-SM.

Androgen receptor mediates the expression of UDP-glucuronosyltransferase 2B15 and B17 genes. Prostate 2008 68;839-48.

74. Lupien M, Eeckhoute J, Meyer CA, Wang Q, Zhang Y, Li W, Carroll JS, Liu XS and Brown

M. FoxA1 translates epigenetic signatures into enhancer driven lineage-specific transcription. Cell. 2008 Mar 21;132(6):958-70.

75. Leleu X, Eeckhoute J, Jia X, Roccaro AM, Moreau AS, Farag M, Sacco A, Ngo HT,

Runnels J, Melham MR, Burwick N, Azab A, Azab F, Hunter Z, Hatjiharissi E, Carrasco DR, Treon SP, Witzig TE, Hideshima T, Brown M, Anderson KC, Ghobrial IM. Targeting NF-κB in Waldenstrom macroglobulinemia. Blood. 2008 May 15;111(10):5068-77.

76. Yang XH, Richardson AL, Torres-Arzayus MI, Zhou P, Sharma C, Kazarov AR, Andzelm

MM, Strominger JL, Brown M, Hemler ME. CD151 accelerates breast cancer by regulating α6 integrin functions, signaling, and molecular organization. Cancer Res. 2008 May 1;68(9):3204-13.

77. Setlur SR, Mertz KD, Hoshida Y, Demichelis F, Lupien M, Perner S, Sboner A, Pawitan Y,

Andrén O, Johnson LA, Tang J, Adami H-O, Calza S, Chinnaiyan AM, Rhodes D, Tomlins S, Fall K, Mucci LA, Kantoff PW, Stampfer M, Andersson S-O, Varenhorst E, Johanson J-E, Brown M, Golub TR, Rubin MA. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst. 2008 Jun 4;100(11):815-25. Epub 2008 May 27.

78. Holmes KA, Song JS, Liu XS, Brown M, Carroll JS. Nkx3-1 and LEF-1 function as

transcriptional inhibitors of estrogen receptor activity. Cancer Res. 2008 Sep 15;68(18):7380-5.

79. Zhang Y, Liu T, Meyer CA, Eeckhoute J, Johnson DS, Myers RM, Brown M, Li W, Liu XS.

Model-based analysis of ChIP-Seq (MACS). ). Genome Biol. 2008 Sep 17;9(9):R137.

30 Myles A. Brown, M.D.

80. Agoulnik IU, Bingman WE, Nakka M, Li W, Wang Q, Liu X, Brown M, Weigel NL. Target gene specific regulation of androgen receptor activity by p42/p44 MAPK. Mol Endocrinol. 2008 Nov;22(11):2420-32. Epub 2008 Sep 11.

81. Krum SA, Miranda-Carboni GA, Lupien M, Eeckhoute J, Carroll JS, Brown M. Unique

ERα cistromes control cell type-specific gene regulation. Mol Endocrinol. 2008 Nov;22(11):2393-406.

82. Hurtado A, Holmes DA, Geistlinger TR, Hutcheson IR, Nicholson RI, Brown M, Jiang J,

Howat WJ, Ali S, Carroll JS. ERBB2 regulation by estrogen receptor-Pax2 determines tamoxifen response. Nature. 2008 Dec 4;456(7222):663-6. Epub 2008 Nov 12.

83. Bhat-Nakshatri P, Wang G, Appaiah H, Luktuke N, Carroll JS, Geistlinger TR, Brown M,

Badve S, Liu Y, Nakshatri H. AKT alters genome-wide estrogen receptor α binding and impacts estrogen signaling in breast cancer. Mol Cell Biol. 2008 Dec;28(24):7487-503. Epub 2008 Oct 6.

84. Eeckhoute J, Lupien M, Meyer CA, Verzi MP, Shivdasani RA, Liu XS, Brown M. Cell-type

selective chromatin remodeling defines the active subset of FoxA1-bound enhancers. Genome Res. 2009 Mar 19(3): 372-380. PMID: 19129543

85. Xia X, Lemieux ME, Li W, Carroll JS, Brown M, Liu XS, Kung AL. Integrative analysis of

HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4260-5. PMID: 19255431

86. Nwachukwu JC, Mita P, Ruoff R, Ha S, Wang Q, Huang SJ, Taneja SS, Brown M, Gerald

WL, Garabedian MJ, Logan SK. Genome-wide impact of androgen receptor trapped clone-27 loss on androgen-regulated transcription in prostate cancer cells. Cancer Res. 2009 Apr 1;69(7):3140-7. PMID: 19318562

87. Sun T, Wang Q, Balk S, Brown M, Lee G-SM, Kantoff P. Roles of microRNA-221 and -222

in castration resistant prostate cancer. Cancer Res. 2009 Apr 15;69(8):3356-63. PMID: 19351832

88. Nucera C, Eeckhoute J, Finn S, Carroll JS, Ligon AH, Priolo C, Fadda G, Toner M, Sheils O, Attard M, Pontecorvi A, Nosè V, Loda M, Brown M. FOXA1 is a potential oncogene in anaplastic thyroid carcinoma. Clin Cancer Res. 2009 Jun 1;15(11):3680-9. PMID: 19470727 89. Lupien M, Eeckhoute J, Meyer CA, Krum SA, Rhodes DR, Liu XS, Brown M. Coactivator

function defines the active estrogen receptor-α cistrome. Mol Cell Biol. 2009 Jun;29(12):3413-23. PMID: 19364822

90. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Lupien M,

Wu T, Regan MM, Meyer CA, Carroll JS, Manrai AK, Jänne OA, Balk SP, Mehra R, Han B, Chinnaiyan AM, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, Kantoff, PW, Liu XS,

31 Myles A. Brown, M.D.

Brown M. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 2009 Jul 23;138(2):245-56. PMC: 2726827

91. Frigo DE, Sherk AB, Wittman BM, Norris JD, Wang Q, Joseph JD, Toner AP, Brown M,

McDonnell DP. Induction of Krüppel-like factor 5 expression by androgens results in increased CXCR4-dependent migration of prostate cancer cell in vitro. Mol Endocrinol. 2009 Sep;23(9):1385-96. PMID: 19460858

92. Bhat-Nakshatri P, Wang G, Collins NR, Thomson MJ, Geistlinger TR, Carroll JS, Brown

M, Hammond S, Srour EF, Liu Y, Nakshatri H. Estradiol-regulated microRNAs control estradiol response in breast cancer cells. Nucleic Acids Res. 2009 Aug;37(14):4850-61. PMID: 19528081

93. Boros J, Donaldson IJ, O'Donnell A, Odrowaz ZA, Zeef L, Lupien M, Meyer CA, Liu XS,

Brown M, Sharrocks AD. Elucidation of the ELK1 target gene network reveals a role in the coordinate regulation of core components of the gene regulation machinery. Genome Res. 2009 Nov;19(11):1963-73. PMID: 19878873

94. Zhang Q, Gu J, Lianjie L, Liu J, Luo B, Cheung H-W, Boehm JS, Root DE, Polyak K, Brown M, Richardson AL, Hahn WC, Kaelin WG, Bommi-Reddy A. Control of cyclin D1 and breast tumorigenesis by the EglN2 prolyl hydroxylase. Cancer Cell. 2009 Nov 6;16(5):413-24.

95. Wade HE, Kobayashi S, Eaton ML, Jansen MS, Lobenhofer EK, Lupien M, Geistlinger TR, Zhu W, Nevins JR, Brown M, Otteson DC, McDonnell DP. Multimodal regulation of E2F1 gene expression by progestins. Mol Cell Biol. 2010 Apr;30(8):1866-77. Epub 2010 Feb 1

96. Wolfer A, Wittner B, Irimia D, Flavin RJ, Lupien M, Gunawardane RN, Meyer CA, Lightcap ES, Tamayo P, Mesirov JP, Liu XS, Shioda T, Toner M, Loda M, Brown M, Brugge JS, Ramaswamy S. Coordinate regulation of twelve poor-outcome cancer signatures by c-MYC. Proc Natl Acad Sci U S A. 2010 Feb 23;107(8):3698-703.

97. He HH, Meyer CA, Shin H, Bailey ST, Wei G, Wang Q, Zhang Y, Xu K, Ni M, Lupien M, Mieczkowski P, Lieb JD, Zhao K, Brown M, Liu XS. Nucleosome dynamics define transcriptional enhancers. Nat Genet. 2010 Apr;42(4):343-7. Epub 2010 Mar 7.

98. Badve S, Collins NR, Bhat-Nakshatri P, Turbin D, Leung S, Thorat M, Dunn SE, Geistlinger TR, Carroll JS, Brown M, Bose S, Teitell MA, Nakshatri H. Subcellular localization of activated AKT in ER and PR expressing breast cancers: potential clinical implications. Am J Pathol. 2010 May;176(5):2139-49. Epub 2010 Mar 12.

99. Torres-Arzayus MI, Zhao J, Bronson R, Brown M. Estrogen-dependent and estrogen-independent mechanisms contribute to AIB1-mediated tumor formation. Cancer Res. 2010 May 15;70(10):4102-11. Epub 2010 May 4.

100. Ahmadiyeh N, Pomerantz MH, Grisanzio C, Herman P, Jia L, Almendro V, He HH, Brown M, Liu XS, Davis M, Caswell JL, Beckwith CA, Hills A, MacConaill L, Coetzee GA, Regan MA, Freedman ML. 8q24 prostate, breast, and colon cancer risk loci show tissue-specific long-range interaction with MYC. Proc Natl Acad Sci U S A. 2010 May 25;107(21):9742-6. Epub 2010 May 7.

32 Myles A. Brown, M.D.

101. Verzi MP, Hatzis P, Sulahian R, Philips J, Schuijers J, Shin H, Freed E, Lynch JP, Dang DT, Brown M, Clevers H, Liu XS, Shivdasani RA. TCF4 and CDX2, major transcription factors for intestinal function, converge on the same cis-regulatory regions. Proc Natl Acad Sci U S A. 2010 Aug 24;107(34):15157-62. Epub 2010 Aug 9.

102. Lupien M, Meyer CA, Bailey ST, Eeckhoute J, Cook J, Westerling T, Zhang X, Carroll JS,

Rhodes DR, Liu XS, Brown M. Growth factor stimulation induces a distinct ERα cistrome underlying breast cancer endocrine resistance. Genes Dev. 2010 Oct 1;24(19):2219-27.

103. Verzi MP, Shin H, He HH, Sulahian R, Meyer C, Montgomery RK, Fleet JC, Brown M, Liu

XS, Shivdasani RA. Differentiation-specific histone modifications reveal dynamic chromatin interactions and alternative partners for the intestinal transcription factor CDX2. Dev Cell. 2010 Nov 16;19(5):713-26.

104. Madak-Erdogan Z, Lupien M, Stossi F, Brown M, Katzenellenbogen BS. Genomic

collaboration of estrogen receptor-α and ERK2 in regulating gene and proliferation programs. Mol Cell Biol. 2011 Jan;31(1):226-36. Epub 2010 Oct 18.

105. Frigo DE, Howe MK, Wittmann BM, Brunner AM, Cushman I, Wang Q, Brown M, Means

AR, McDonnell DP. CaM kinase kinase β-mediated activation of the growth regulatory kinase AMPK is required for androgen-dependent migration of prostate cancer cells. Cancer Res. 2011 Jan 15;71(2):528-37. Epub 2010 Nov 22.

106. Sérandour A, Avner S, Percevault F, Demay F, Bizot M, Lucchetti-Miganeh C, Barloy-

Hubler F, Brown M, Lupien M, Métivier R, Salbert G, Eeckhoute J. Epigenetic switch involved in activation of pioneer factor FOXA1-dependent enhancers. Genome Res. 2011 Apr;21(4):555-65. Epub 2011 Jan 13.

107. Flavin RJ, Cook J, Fiorentino M, Bailey D, Brown M, Loda MF. Beta-Catenin is a useful

adjunct immunohistochemical marker for the diagnosis of pulmonary lymphagnioleiomyomatosis. Am J Clin Pathol. 2011 May;135(5):776-82.

108. Baba A, Ohtake F, Okuno Y, Yokota K, Okada M, Imai Y, Ni M, Meyer CA, Igarashi K,

Kanno J, Brown M, Kato S. PKA-dependent regulation of the histone lysine demethylase complex PHF2-ARID5B. Nat Cell Biol. 2011 Jun;13(6):668-75. Epub 2011 May 1.

109. Meyer CA, He HH, Brown M, Liu XS. BINOCh: Binding inference from nucleosome

occupancy changes. Bioinformatics. 2011 Jul 1;27(13):1867-8. Epub 2011 May 5. 110. Yang M, Xie W, Mostaghel E, Nakabayashi M, Werner L, Sun T, Pemerantz M, Freedman

M, Ross R, Regan M, Sharifi N, Figg WD, Balk S, Brown M, Taplin ME, Oh WK, Lee GSM, Kantoff PW. SLCO2B1 and SLCO1B3 may determine time to progression for patients receiving androgen deprivation therapy for prostate cancer. J Clin Oncol. 2011 Jun 20;29(18):2565-73. Epub 2011 May 23.

33 Myles A. Brown, M.D.

111. Ni M, Chen Y, Lim E, Wimberly H, Bailey ST, Imai Y, Rimm DL, Liu XS, Brown M. Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell. 2011 Jul 12;20(1):119-31.

112. Liu T, Ortiz JA, Taing L, Meyer CA, Lee B, Zhang Y, Shin H, Wong SS, Ma J, Lei Y, Pape

UJ, Poidinger M, Chen Y, Yeung K, Brown M, Turpaz Y, Liu XS. Cistrome: an integrative platform for transcriptional regulation studies. Genome Biol. 2011 Aug 22;12(8):R83. [Epub ahead of print]

113. Wang C, Mayer JA, Mazumdar A, Fertuck K, Kim H, Brown M, Brown PH. Estrogen

induces c-myc gene expression via an upstream enhancer activated by the estrogen receptor and the AP-1 transcription factor. Mol Endocrinol. 2011 Sep;25(9):1527-38.

114. Zhang C, Wang L, Wu D, Chen H, Chen Z, Thomas-Ahner J, Zynger D, Eeckhoute J, Yu J, Luo J, Brown M, Clinton SK, Nephew KP, Huang TH, Li W, Wang Q. Definition of a FoxA1 cistrome that is crucial for G1-S phase cell-cycle transit in castration-resistant prostate cancer. Cancer Res. 2011 Nov 1;71(21):6738-6748.

115. Cai C, He HH, Chen S, Coleman I, Wang H, Fang Z, Chen S, Nelson PS, Liu XS, Brown M,

Balk SP. Androgen receptor gene expression in prostate cancer is directly suppressed by the androgen receptor through recruitment of lysine specific demethylase 1. Cancer Cell. 2011 Oct 18;20(4):457-71.

116. Tang Q, Chen Y, Meyer CA, Geistlinger T, Lupien M, Wang Q, Liu T, Zhang Y, Brown M,

Liu XS. A comprehensive view of nuclear receptor cancer cistromes. Cancer Res. 2011 Nov 15;71(22):6940-7.

117. Fujiki R, Hashiba W, Sekine H, Yokoyama A, Chikanishi T, Ito S, Imai Y, Kim J, He HH,

Igarashi K, Kanno J, Ohtake F, Kitagawa H, Roeder RG, Brown M, Kato S. GlcNAcylation of histone H2B facilitates its monoubiquitination. Nature 2011 Nov 27;480(7378):557-60.

118. Sun T, Yang M, Chen S, Balk S, Pomerantz M, Hsieh CL, Brown M, Lee GS, Kantoff PW.

The altered expression of MiR-221/-222 and MiR-23b/-27b is associated with the development of human castration resistant prostate cancer. Prostate. 2012 Jul 1;72(10):1093-103. doi: 10.1002/pros.22456. Epub 2011 Nov 29.

119. He HH, Meyer CA, Chen MW, Jordan VC, Brown M, Liu XS. Differential DNase I

hypersensitivity reveals factor-dependent chromatin dynamics. Genome Res. 2012 Jun;22(6):1015-25. Epub 2012 Apr 16.

120. Villa H, Della Torre S, Stell A, Cook J, Brown M, Maggi A. Tetradian oscillation of

estrogen receptor α is necessary to prevent liver lipid deposition. Proc Natl Acad Sci USA. 2012 July 17;109(29):11806-11.

34 Myles A. Brown, M.D.

121. Bailey ST, Shin H, Westerling T, Liu XS, Brown M. Estrogen receptor prevents p53-dependent apoptosis in breast cancer. Proc Natl Acad Sci USA. 2012 Oct 30;109(44):18060-5.

122. Xu K, Wu ZJ, Groner AC, He HH, Cai C, Lis RT, Wu X, Stack EC, Loda M, Liu T, Xu H,

Cato L, Thornton JE, Gregory RI, Morrissey C, Vessella RL, Montironi R, Magi-Galluzzi C, Kantoff PW, Balk SP, Liu XS, Brown M. EZH2 oncogenic activity in castration resistant prostate cancer cells is polycomb-independent. Science 2012 Dec 14;338(6113):1465-9.

123. Li Q, Seo J-H, Stranger B, McKenna A, Pe’er I, LaFrancoise T, Brown M, Tyekucheva S,

Freedman ML. Integrative eQTL-based analyses reveal the biology of breast cancer risk loci. Cell 2013 Jan 31;152(3):633-41.

124. Cai C, Wang H, He HH, Chen S, He L, Ma F, Mucci L, Wang Q, Fiore C, Sowalsky AG,

Loda M, Liu XS, Brown M, Balk SP, Yuan X. ERG induces androgen receptor-mediated regulation of SOX9 in prostate cancer. J Clin Invest 2013 Mar 1;123(3):1109-22.

125. Sun H, Qin B, Liu T, Wang Q, Liu J, Wang J, Lin X, Yang Y, Taing L, Rao PK, Brown M,

Zhang Y, Long HW, Liu XS. CistromeFinder for ChIP-seq and DNase-seq data reuse. Bioinformatics. 2013 May 15;29(10):1352-1354. Epub 2013 Mar 18.

126. Ni M, Chen Y, Fei T, Li D, Lim E, Liu XS, Brown M. Amplitude modulation of androgen

signaling by c-MYC. Genes Dev. 2013 Apr 1;27(7):734-748. Epub 2013 Mar 25. 127. Jeselsohn RM, Werner L, Regan MM, Fatima A, Gilmore L, Collins LC, Beck AH, Bailey

ST, He HH, Buchwalter G, Brown M, Iglehart JD, Richardson A, Come S. Digital quantification of gene expression in sequential breast cancer biopsies reveals activation of an immune response. PLoS One. 2013 May 31;8(5):e64225.

128. Buchwalter G, Hickey MM, Cromer A, Selfors LM, Gunawardane RN, Frishman J,

Jeselsohn R, Lim E, Chi D, Fu X, Schiff R, Brown M, Brugge JS. PDEF promotes luminal differentiation and acts as a survival factor in ER-positive breast cancer cells. Cancer Cell. 2013 Jun 10;23(6):753-67.

129. Du Z, Fei T, Verhaak RGW, Su Z, Zhang Y, Brown M, Chen Y, Liu XS. Integrative

genomic analyses reveal clinically relevant long non-coding RNA in human cancer. Nat Struct Mol Biol. 2013 Jun 2. doi: 10.1038/nsmb.2591. [Epub ahead of print]

130. Bhat-Nakshatri P, Song EK, Collins NR, Uversky VN, Dunker AK, O’Malley BW,

Geistlinger TR, Carroll JS, Brown M, Nakshatri H. Interplay between estrogen receptor and AKT in estradiol-induced alternative splicing. BMC Med Genomics. 2013 Jun 11;6:21.

131. Sun T, Wang X, He HH, Sweeney CJ, Liu XS, Brown M, Balk S, Lee GSM, Kantoff PW.

MiR-221 promotes the development of androgen independence in prostate cancer cells via downregulation of HECTD2 and RAB1A. Oncogene. 2013 Jun 17. doi: 10.1038/onc.2013.230. [Epub ahead of print]

35 Myles A. Brown, M.D.

132. Tam WL, Lu H, Buikhuisen J, Soh BS, Lim E, Reinhardt F, Wu ZJ, Krall JA, Bierie B, Guo W, Chen X, Liu XS, Brown M, Lim B, Weinberg RA. Protein kinase C alpha is a central signaling node and therapeutic target for breast cancer stem cells. Cancer Cell. 2013 Sep 9;24(3):347-64.

133. McLaughlin SK, Olsen SN, Dake B, De Raedt T, Lim E, Bronson RT, Beroukhim R, Polyak

K, Brown M, Kuperwasser C, Cichowski K. The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. Cancer Cell. 2013 Sep 9;24(3):365-78.

134. Merenbakh-Lamin K, Ben-Baruch N, Yeheskel A, Dvir A, Soussan-Gutman L, Jeselsohn R,

Yelensky R, Brown M, Miller VA, Sarid D, Rizel S, Klein B, Rubinek T, Wolf I. D538G Mutation in estrogen receptor-α: a novel mechanism for acquired endocrine resistance in breast cancer. Cancer Res. 2013 Dec 1;73(23):6856-64.

135. Pfefferle AD, Herschkowitz JI, Usary J, Harrell JC, Spike BT, Adams JR, Torres-Arzayus

MI, Brown M, Egan SE, Wahl GM, Rosen JM, Perou CM. Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts. Genome Biol. 2013 Nov 12;14(11):R125.

136. He HH, Meyer CA, Hu SS, Chen MW, Zang C, Liu Y, Rao PK, Fei T, Xu H, Long H, Liu

XS, Brown M. Refined DNase-seq protocol and data analysis reveals intrinsic bias in transcription factor footprint identification. Nat Methods. 2014 Jan;11(1):73-8.

137. Bailey ST, Miron PL, Choi YJ, Kochupurakkal B, Maulik G, Rodig SJ, Tian R, Foley KM,

Bowman T, Miron A, Brown M, Iglehart JD, Biswas DK. Nuclear factor kappa B activation-induced anti-apoptosis renders HER2 positive cells drug resistant and accelerates tumor growth. Mol Cancer Res. 2014 Mar;12(3):408-20.

138. Jeselsohn R, Yelensky R, Buchwalter G, Frampton GM, Meric-Bernstam F, Gonzalez-

Angulo AM, Ferrer-Lozano J, Perez-Fidalgo A, Cristofanilli M, Gomez H, Arteaga CL, Giltnane J, Balko JM, Cronin MT, Jarosz M, Sun J, Hawryluk M, Lipson D, Otto G, Ross J, Dvir A, Soussan-Gutman L, Wolf I, Rubinek T, Gilmore L, Schnitt SJ, Come SE, Pusztai L, Stephens PJ, Brown M, Miller VA. Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor positive breast cancer. Clin Cancer Res. 2014 Apr 1;20(7):1757-67.

139. Jehle K, Cato L, Neeb A, Muhle-Goll C, Jung N, Smith EW, Buzon V, Carbo LR,

Estebanez-Perpina E, Schmitz K, Fruk L, Luy B, Chen Y, Cox MB, Brase S, Brown M, Cato AC. Coregulator control of androgen receptor action by a novel nuclear receptor-binding motif. J Biol Chem. 2014 Mar 28;289(13):8839-51.

140. Chen X, Iliopoulos D, Zhang Q, Tang Q, Greenblatt MB, Hatziapostolou M, Lim E, Tam

WL, Ni M, Chen Y, Mai J, Shen H, Hu DZ, Adoro S, Hu B, Song M, Tan C, Landis MD, Ferrari M, Shin SJ, Brown M, Chang JC, Liu XS, Glimcher LH. XBP1 promotes triple-negative breast cancer by controlling the HIF1α pathway. Nature. 2014 Apr 3;508(7494):103-7.

36 Myles A. Brown, M.D.

141. Hsieh CL, Fei T, Chen Y, Li T, Gao Y, Wang X, Sun T, Sweeney CJ, Lee GS, Chen S, Balk SP, Liu XS, Brown M, Kantoff PW. Enhancer RNAs participate in androgen receptor-driven looping that selectively enhances gene activation. Proc Natl Acad Sci U S A. 2014 May 20;111(20):7319-24.

37 Myles A. Brown, M.D.

Proceedings of Meetings: 1. Carroll PR, Kantoff PW, Balk SP, Brown MA, D'amico AV, George DJ, Grossfeld GD,

Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, Mcleod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart C. Second International Conference on Newer Approaches to Androgen Deprivation Therapy (ADT) in Prostate Cancer. Urology 2002 60(3 Suppl 1):1-6.

2. Come SE, Buzdar AU, Ingle JN, Arteaga CL, Brown M, Dowsett M, Hilsenbeck SG, Kumar

R, Johnston SR, Lee AV, Paik S, Pritchard KI, Winer EP, Hart C. Proceedings of the Fifth International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: conference summary statement. Clin Cancer Res. 2006 Feb 1;12(3 Pt 2):997s-1000s.

3. Come SE, Buzdar AU, Arteaga CL, Bissell MJ, Brown MA, Ellis MJ, Goss PE, Green JE,

Ingle JN, Lee AV, Medina D, Nicholson RI, Santen RJ, Schiff R, Hart CS. Proceedings of the Third International Conference on Recent Advances and Future Directions in Endocrine Manipulation of Breast Cancer: conference summary statement. Clin Cancer Res. 2004 Jan 1;10(1 Pt 2):327S-330S.

4. Li W, Carroll JS, Brown M, Liu S. xMAN: extreme MApping of oligoNucleotides. BMC

Genomics. 2008;9 Suppl 1:S20. Reviews, Chapters, and Editorials: 1. Cherington V, Gee C, Brown M, Paucha E, Spiegelman B, Roberts TM. Analysis of the

effects of polyoma and SV40 large T antigens on differentiation. In: Alt FW, Harlow E, Ziff EB, eds. Nuclear Oncogenes, Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1988.p.138-43.

2. Glass CK, Brown MA. Molecular Mechanisms of Estrogen and Thyroid Hormone Action.

In: Noda, M. ed. Molecular and Cellular Biology of Bone, New York, NY: Academic Press; 1993.p. 257–85.

3. Brown M. Estrogen Receptor Molecular Biology. In: Henderson IC, Shapiro CL, eds.

Hematology/Oncology Clinics of North America, Philadelphia, PA: WB Saunders; 1994; Vol 8, p. 101–12.

4. Kantoff P, Giovannucci E, Brown M. The androgen receptor CAG repeat polymorphism

and its relationship to prostate cancer. Biochemica et Biophysica Acta 1998; 1378:1- 5. 5. Miner JN, Brown M. Glucocorticoid Acion. In: Austen S, Burakoff SJ, et al., eds.

Therapeutic Immunology, 2nd edition, London, UK: Blackwell Science; 2000.p. 103-06.

38 Myles A. Brown, M.D.

6. Febbo PG, Brown MA. Nuclear Receptors in Normal Prostatic Growth and Disease. In: Kantoff PW, et al., eds. Prostate Cancer: Principles and Practice, Philadelphia, PA: Lippincott Williams & Wilkins; 2002. p.29-52.

7. Carroll PR, Kantoff PW, Balk SP, Brown MA, D'amico AV, George DJ, Grossfeld GD,

Johnson CS, Kelly WK, Klotz L, Lee WR, Lubeck DP, Mcleod DG, Oh WK, Pollack A, Sartor O, Smith MR, Hart C. Overview consensus statement. Newer approaches to androgen deprivation therapy in prostate cancer. Urology. 2002;60:(3 Suppl 1):1-6.

8. Keeton EK, Brown M. Coregulator Expression and Breast Cancer: Improving the Predictive

Power of Estrogen Receptor alpha. [Editorial]. Clin Cancer Res, 2003. 9(4):1229-30. 9. Shao WL. Brown M. Advances in estrogen receptor biology: prospects for improvements in

targeted breast cancer therapy. [review]. Breast Cancer Res. 2004;6(1):39-52. Epub 2003 Nov 07.

10. Carroll JS, Brown M. Estrogen receptor target gene: an evolving concept. [minireview]. Mol

Endocrinol 2006 Jan 5; [Epub ahead of print]. 11. Krum, SA, Brown, M. Unraveling estrogen action in osteoporosis. Cell Cycle 2008

May;7(10):1348-52. Epub 2008 Feb 29. 12. Lupien M, Brown M. Cistromics of hormone-dependent cancer. Endocr Relat Cancer. 2009

Jun;16(2):381-9. Epub 2009 Apr 15. Review. PMID: 19369485 13. Eeckhoute J, Lupien M, Brown M. Combining Chromatin Immunoprecipitation and

Oligonucleotide Tiling Arrays (ChIP-Chip) for Functional Genomic Studies. Methods Mol Biol. 2009;556:155-64. PMID: 19488877

14. Scott SM, Brown M, Come SE. Emerging data on the efficacy and safety of fulvestrant, a

unique antiestrogen therapy for advanced breast cancer. Expert Opin Drug Saf. 2011 Sep;10(5):819-26.

15. Lim E, Ni M, Hazra A, Tamimi R, Brown M. Elucidating the role of androgen receptor in

breast cancer. Clinical Investigation 2012; 2(10):1003-11. 16. van Kruchten M, de Vries EG, Brown M, Glaudemans AW, Dierckx RA, Schröder CP,

Hospers GA. PET imaging of oestrogen receptors in patients with breast cancer. Lancet Oncol. 2013 Oct;14(11):e465-75.

17. Lim E, Ni M, Cao S, Hazra A, Tamimi RM, Brown M. Importance of Breast Cancer

Subtype in the Development of Androgen Receptor Directed Therapy. Curr Breast Cancer Rep. 2014 Jun 1;6(2):71-78.

39 Myles A. Brown, M.D.

Clinical Communications: 1. Anderson P, Macklis J, Brown M, Ory D. Eosinophilic cerebrospinal fluid pleocytosis and

cryptococcal meningitis. Ann Intern Med 1985 Aug;103(2):306-7. Patents: 1. Kantoff PW, Brown M, Giovannucci E, inventors. Method for predicting the risk of prostate

cancer morbidity and mortality. US patent 6,300,060. 2001 October 9.

40 Myles A. Brown, M.D.